Aprea Therapeutics (APRE)
Nasdaq Market Closed
Aprea Therapeutics, Inc. is a clinical-stage biotechnology company developing precision oncology treatments for patients whose cancers are driven by identifiable genetic vulnerabilities. The company’s work centres on small-molecule drug candidates designed to interfere with DNA damage response and cell-cycle control mechanisms that cancer cells often depend on for survival. By targeting these weaknesses, Aprea aims to create therapies that can attack tumour cells more selectively while limiting harm to normal tissue.
Its pipeline includes APR-1051, a WEE1 inhibitor being developed for biomarker-selected cancer populations. WEE1 is an important checkpoint kinase involved in regulating cell division, and inhibiting it may increase the susceptibility of cancer cells to DNA damage. Aprea is also advancing ATRN-119, also known as mosipasertib, an oral inhibitor of ATR, another key protein in the DNA damage response pathway. ATR inhibition is being explored across oncology because many tumours rely on this repair signalling to manage replication stress and genomic instability.
In addition to its clinical candidates, Aprea maintains earlier-stage research programs such as APR-1602, which broaden its approach to synthetic lethality and targeted cancer biology. As a listed stock, APRE gives investors exposure to a high-risk, research-driven oncology business where value depends heavily on clinical trial progress, regulatory outcomes, financing capacity, and the ability to demonstrate meaningful benefit in defined patient groups.
Last updated
- Market Cap
- 9.41M
- P/E
- —
- P/FCF
- —
- P/S
- 76.33
- Enterprise Value
- -37.06M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 9.41M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -37.06M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.23
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 76.33
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 2.95
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- -300.54
- EPS
- -0.97
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -28.75%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -25.11%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 8.92
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 8.92
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 8.77
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 179.2K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.76
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | 3.34K | 1.85K | 118.11K | 162.46K |
| Gross profit | — | 3.34K | 1.85K | 118.11K | 162.46K |
| Operating income | -3.43M | -2.64M | -3.12M | -3.39M | -4.09M |
| EBITDA | -3.42M | -2.64M | -3.11M | -3.38M | -4.08M |
| Net income | -3.29M | -2.46M | -2.97M | -3.24M | -3.93M |
| Basic EPS | -0.22 | -0.28 | -0.47 | -0.53 | -0.66 |
| Diluted EPS | -0.22 | -0.28 | -0.47 | -0.53 | -0.66 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 47.61M | 15.93M | 14.32M | 17.31M | 20.22M |
| Total liabilities | 5.3M | 2.76M | 2.68M | 3.17M | 3.36M |
| Total equity | 41.59M | 12.44M | 10.91M | 13.41M | 15.55M |
| Cash & equivalents | 46.47M | 14.6M | 13.72M | 16.53M | 19.28M |
| Current assets | 47.25M | 15.56M | 13.94M | 16.93M | 19.83M |
| Current liabilities | 5.3M | 2.76M | 2.68M | 3.17M | 3.36M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -2.76M | -2.96M | -3.17M | -3.13M | -3.63M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | 34.62M | 3.84M | 357.94K | 384.88K | 55.85K |
| Change in cash | 31.87M | 880.28K | -2.81M | -2.75M | -3.58M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 424B7 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | UPLOAD — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | CORRESP — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | S-3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | PRE 14A — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Peters Richard | View Filing | |
| form 4 | Form 4 — Peters Richard | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | EFFECT — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | S-3/A — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 10-K — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | S-8 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| edgar index | S-3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aprea Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | D — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | EFFECT — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | S-3 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Aprea Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Gilad Oren | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Hamill John P. | View Filing | |
| form 4 | Form 4 — Duey Marc | View Filing |